Term
|
Definition
Study showed if patient is 20/40 with well perfused macula then grid laser photocoagulation is indicated (set standard of care) |
|
|
Term
|
Definition
Tested steroid (triamcinolone) injection for RVO against standard of care. Steroid less effective. |
|
|
Term
|
Definition
Tested injection of lucentis vs. laser photocoagulation for BRVO. Lucentis showed better results |
|
|
Term
|
Definition
Tested lucentis for CRVO vs. monitor, dramatic improvement. Did not differentiate between ischemic and non-ischemic. |
|
|
Term
|
Definition
Early treatment for diabetic retinopathy involving focal and grid IVFA guided laser therapy. Stabilized vision, but did not improve (though exudate and edema did resolve over a long period of time). Also stated laser therapy should be avoided where there is loss of macular perfusion. |
|
|
Term
|
Definition
Lucentis for diabetic macular edema vs. focal/grid laser. Also compared to combination of lucentis and laser therapy. Lucentis alone showed greatest improvement. |
|
|
Term
|
Definition
Lucentis .3 mg vs .5mg vs. placebo (sham) for diabetic macular edema. Lucentis of both quantitis improved (somewhat equally) vision greater than laser. |
|
|
Term
|
Definition
Lucentis 0.5 mg with and without laser. All patients thought they were receiving both treatments. Lucentis preformed best alone. |
|
|
Term
|
Definition
|
|
Term
|
Definition
Standard control of diabetes vs. intensive control. Intensive control of diabetes greatly decreased complications (76%) |
|
|
Term
|
Definition
Fluocinolone acetonide intravitreal insert for macular edema secondary to RVO |
|
|
Term
|
Definition
Lucentis vs. avastin. Showed lucentis decreased macular thickness more effectively, but both were fairly comparable. |
|
|
Term
|
Definition
Long term control of macular edema with laser photocoagulation after anti-VEGF. Compares lucentis .5 mg vs 2 mg dose |
|
|
Term
|
Definition
Tested the impact on the quality of life of patients who received multiple intravitreal injections. |
|
|
Term
|
Definition
Lucentis for ischemic CRVO. Ongoing |
|
|